Please ensure Javascript is enabled for purposes of website accessibility

3 Small-Caps That Are Soaring Because of Coronavirus Panic

By Taylor Carmichael - Feb 28, 2020 at 7:01PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Some of the top stocks in 2020 are the companies that are fighting the coronavirus.

While the coronavirus has walloped the stock market this week, many traders have jumped into a safe haven: small-cap healthcare companies that are fighting the disease. For instance, Novavax (NVAX -6.90%) has been on a tear all year. The tiny biotech started off 2020 with its stock priced at $3.99 a share; now, the stock sells for $16.

Vir Biotechnology (VIR -1.79%) has had a similar rocket ride. The company had a broken IPO last year and it's up 282% in 2020.

But the biggest winner has been tiny Co-Diagnostics (CODX -2.31%). The Utah diagnostic company started the year as a micro cap. Its stock has had an amazing run in 2020, up 1,353% in two months.

dollar arrow going up

Image source: Getty Images.

How are the large caps doing?

There are probably a dozen healthcare companies that are working on a vaccine or cure for the coronavirus. These include mega-cap names like SanofiJohnson & Johnson, and GlaxoSmithKline, as well as larger biotechs like ModernaGilead Sciences, and Regeneron. Yet the market has been rewarding these names only slightly, and in some cases, not at all.

Stock Price on January 2 Price on February 28 Percentage Return
Johnson & Johnson $145.87 $134.48 (7.9%)
Sanofi $50.58 $46.25 (8.7%)
GlaxoSmithKline $46.81 $40.53 (13.6%)
Gilead Sciences $65.53 $69.36 6.3%
Regeneron $378 $444.57 19.08%
Moderna $19.57 $25.93 34.84%
Vir Biotechnology $12.56 $46.50 282%
Novavax $3.99 $16 300%
Co-Diagnostics $0.90 $13.23 1,353%

Chart by author.

The small-cap names have done much, much better than the mega caps. For investors looking for a safe haven in the coronavirus meltdown, smaller is probably better. 

Taylor Carmichael owns shares of Novavax. The Motley Fool owns shares of and recommends Gilead Sciences. The Motley Fool recommends Johnson & Johnson. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Novavax, Inc. Stock Quote
Novavax, Inc.
$39.92 (-6.90%) $-2.96
Vir Biotechnology, Inc. Stock Quote
Vir Biotechnology, Inc.
$26.27 (-1.79%) $0.48
Co-Diagnostics, Inc. Stock Quote
Co-Diagnostics, Inc.
$4.01 (-2.31%) $0.10
Sanofi Stock Quote
$41.64 (-7.07%) $-3.17
Johnson & Johnson Stock Quote
Johnson & Johnson
$168.02 (0.27%) $0.45
Gilead Sciences, Inc. Stock Quote
Gilead Sciences, Inc.
$66.68 (0.53%) $0.35
Regeneron Pharmaceuticals, Inc. Stock Quote
Regeneron Pharmaceuticals, Inc.
$643.57 (-0.79%) $-5.13
GSK Stock Quote
$34.55 (-2.01%) $0.71
Moderna, Inc. Stock Quote
Moderna, Inc.
$158.97 (-5.35%) $-8.99

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/17/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.